{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:29:18Z","timestamp":1783798158005,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The combination of neoadjuvant chemotherapy and immunotherapy (NICT) brings a higher proportion of pathological complete response (pCR) compared with neoadjuvant chemotherapy for locally advanced gastric cancer (LAGC). Here we constructed and validated a prediction model to provide a clinical reference for predicting pCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>456 patients who accepted radical gastrectomy after NICT in seven large-scale gastrointestinal medical centers from Jan 2020 to Jan 2025 were enrolled in this study, with 320 patients in the training set and 136 patients in the validation set. The uni- and multivariate logistic regression model were used to evaluate the factors influencing pCR and a nomogram model was constructed. The area under the receiver operating characteristic curve (AUC), the calibration curve and decision curve analysis (DCA) were used to evaluate the discrimination, accuracy and clinical value of the nomogram model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the baseline characteristics between training and validation set. The pCR and MPR rates were respectively 16.2% and 39.5%. Complete response by abdominal enhanced CT, less diameter of tumor bed, non-signet-ring cell, ages\u226570 years old, and CEA&amp;lt;4.25 ng\/mL were proved as the independent predictors for pCR (P&amp;lt;0.05). The nomogram model showed that the AUC (95%CI) predicting the pCR were 0.862 (95% CI: 0.807-0.916) in the training set and 0.934(95%CI: 0.889-0.979) in the validation set. The calibration curves showed that the prediction curve of the nomogram was good in fit with the actual pCR in the training and validation set respectively (Hosmer-Lemeshow test: \u03c72\u00a0=\u00a09.093, P=0.168; \u03c72\u00a0=\u00a02.853, P=0.827). Decision curve analysis showed a good outcome to assess net benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our nomogram model could provide satisfactory predictive effect for the pCR in LAGC patients with NICT, which proves to be a valuable approach for surgeons to make personalized strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1603196","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:10:22Z","timestamp":1752811822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of nomogram for predicting pathological complete response to neoadjuvant chemotherapy and immunotherapy for locally advanced gastric cancer: a multicenter real-world study in China"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13151-w","article-title":"Tumor regression grade and overall survival following gastrectomy with preoperative therapy for gastric cancer","volume":"30","author":"Sinnamon","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6597","article-title":"Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma","volume":"12","author":"Yin","year":"2023","journal-title":"Cancer Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-021-01785-7","article-title":"Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41598-023-33038-w","article-title":"Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer","volume":"13","author":"Ma","year":"2023","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6349(08)71964-5","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1083840","article-title":"Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2023-0133","article-title":"Development and validation of web-based risk score predicting prognostic nomograms for elderly patients with primary colorectal lymphoma: A population-based study","volume":"12","author":"Wang","year":"2025","journal-title":"J Transl Int Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001793","article-title":"Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in asia","volume":"265","author":"Chon","year":"2017","journal-title":"Ann Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02350-6","article-title":"Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets","volume":"41","author":"Puccini","year":"2022","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01403-1","article-title":"Gastrointestinal signet ring cell Malignancy: current advancement and future prospects","volume":"41","author":"Hong","year":"2023","journal-title":"Invest New Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2023.03.008","article-title":"Single-cell profiling of tumor immune microenvironment reveals immune irresponsiveness in gastric signet-ring cell carcinoma","volume":"165","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010115","article-title":"Comprehensive analysis of clinicopathological and molecular features to predict anti-PD-1-based therapy efficacy in patients with advanced gastric signet ring cell carcinoma","volume":"13","author":"Hu","year":"2023","journal-title":"J Pers Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512192","article-title":"Using normalized carcinoembryonic antigen and carbohydrate antigen 19 to predict and monitor the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer","volume":"24","author":"Tang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114044","article-title":"Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial","volume":"204","author":"Zwart","year":"2024","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2023.02.005","article-title":"Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis","volume":"68","author":"Nurczyk","year":"2023","journal-title":"Adv Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-751","article-title":"Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies","volume":"14","author":"Li","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47763","article-title":"Assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma using image-guided clip placement","volume":"15","author":"Pandurangappa","year":"2023","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non\u2013small-cell lung cancer after neoadjuvant chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01141-4","article-title":"Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms","volume":"35","author":"Mayer","year":"2022","journal-title":"Mod Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41467-023-37179-4","article-title":"Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients","volume":"14","author":"Tsai","year":"2023","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","article-title":"Emerging and evolving concepts in cancer immunotherapy imaging","volume":"306","author":"Dercle","year":"2023","journal-title":"Radiology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24513","article-title":"Molecular key to understand the gastric cancer biology in elderly patients\u2014the role of microsatellite instability","volume":"115","author":"Polom","year":"2017","journal-title":"J Surg Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109599","article-title":"Evaluating the impact of age on immune checkpoint therapy biomarkers","volume":"36","author":"Erbe","year":"2021","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12957-021-02157-x","article-title":"Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer","volume":"19","author":"Jiang","year":"2021","journal-title":"World J Surg Onc"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5294-0","article-title":"Treatment interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients: A population-based study","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00426-X","article-title":"The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection","volume":"7","author":"Patel","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","volume":"6","author":"Bakos","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase II trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treat-ment","volume":"25","author":"O'Donnell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221139625","article-title":"Immune checkpoint inhi-bitors in resectable gastroesophageal cancers-a review","volume":"14","author":"Mukherjee","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:10:23Z","timestamp":1752811823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2025.1603196"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1603196","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1603196"}}